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ej@pbrc.eduAbstract Thiazolidinedione (TZD) is a powerful insulin sensitizer in the treatment of type 2
diabetes. It acts as a ligand to the nuclear receptor PPARg (peroxisome proliferator-activated
receptor-gamma) and induces transcription of PPARg-responsive genes. TZD controls lipid
synthesis and storage in adipose tissue, liver and many other tissues through PPARg. Derivatives
of TZD, such as rosiglitazone (Avandia) and pioglitazone (Actos), are more powerful than
metformin or berberine in insulin sensitization. Although they have common side effects such as
weight gain and edema, these did not inﬂuence their clinical application in general. However, recent
ﬁndings of risk for congestive heart failure and bladder cancer have signiﬁcantly impaired their
future in many countries. European countries have prohibited those drugs, and US will terminate
application of rosiglitazone in clinics and hospitals. The multiple country actions may mark the end
of TZD era. As a result, there is a strong demand for identiﬁcation of TZD substitute in the
treatment of type 2 diabetes. In this regard, literature about PPARg ligands and potential TZD
substitute are reviewed in this article. Histone deacetylase (HDAC) inhibitor is emphasized as a
new class of insulin sensitizer here. Regulators of SIRT1, CREB, NO, p38, ERK and Cdk5 are
discussed in the activation of PPARg.
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Figure 1 Regulation of PPARg function in cells.
Jian-ping Ye1381. Introduction
Thiazolidinedione (TZD) is a powerful insulin sensitizer in the
treatment of type 2 diabetes, a disease that is associated with
obesity and aging through insulin resistance. With prevalence
of obesity and increased lifespan in industrial countries,
incidence of type 2 diabetes is increased quickly worldwide.
In the treatment of type 2 diabetes, restoration of insulin
sensitivity is a major strategy. Currently, there are several
classes of drugs available in the treatment of insulin resistance.
They are metformin, TZDs (Avandia and Actos), berberine,
meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, and
glucagon-like peptide-1 receptor agonists. Among those,
TZD-based drugs are the most powerful medicines among
these insulin sensitizers. There are two widely used commercial
products derived from TZD, rosiglitazone (Avandia), and
pioglitazone (Actos). The two medicines have common side
effects such as weight gain and edema. However, rosiglitazone
and muraglitazone have recently been reported to increase risk
for congestive heart failure and risk for bone fractures1. The
heart attack is lethal and not acceptable in the treatment of
type 2 diabetes. As a result, the European Medicines Agency
(EMA) recommended in September 2010 to suspend rosigli-
tazone (Avandia) from the European market. In US, rosigli-
tazone will be removed from the retail pharmacy stores by
November 18th in 2011. In this case, pioglitazone will be the
only TZD-based drug available in the US and European
markets. However, pioglitazone has been reported to increase
risk for bladder cancer in two recent reports2,3. In response,
application of rosiglitazone has been suspended in the treat-
ment of type 2 diabetes in some European counties (France
and Italy) in June 2011. FDA in US has issued a warning to
doctors and patients about the risk of bladder cancer from
pioglitazone. Pioglitazone is the fourth drug in the thiazolidi-
nedione class that has signiﬁcant adverse clinical events:
troglitazone (Rezulin) is the ﬁrst with massive hepatic necrosis;
muraglitazone (Pargluva, not marketed) and rosiglitazone
(Avandia) are the second and third with increased cardiovas-
cular events; and now pioglitazone is the fourth with bladder
cancer. The risk of blander cancer may restrict pioglitazone
application in the treatment of type 2 diabetes worldwide
soon. It is now clear that a substitute for TZD is in demand
for correction of insulin resistance in the treatment of type 2
diabetes. In this aspect, I like to provide this review to
facilitate our search for TZD substitute.2. PPARc ligand
2.1. Synthetic ligand
TZD is a synthetic ligand of the nuclear receptor PPARg
(peroxisome proliferator-activated receptor gamma)4 (Fig. 1).
This class of insulin sensitizers include rosiglitazone (commer-
cial name ‘‘Avandia’’ from GlaxoSmithKline, GSK), pioglita-
zone (Actos from Takeda Pharmaceuticals), muraglitazone,
englitazone, ciglitazone and troglitazone5. Rosiglitazone binds
to PPARg with a high afﬁnity (Kd of 40 nmol/L), whereas
pioglitazone, englitazone, and ciglitazone were less potent
ligands of PPARg. In vivo, activation of PPARg by these
compounds is required for the insulin-sensitizing actions of the
TZD-based drugs. Gene knockout studies in mice suggest thatthe PPARg activation in adipose tissue, skeletal muscle and
macrophages are involved in the therapeutic activities of TZD
for insulin sensitization. GW2570 is a very potent non-TZD
PPARg-selective agonist that was recently shown to have anti-
diabetic efﬁcacy in humans5.
2.2. Fatty acid ligand
Fatty acid and their derivatives are PPARg ligands (Fig. 1).
The search for natural ligands for PPARg begins with fatty
acids and eicosanoids. Cell-based transactivation assays and
direct binding studies are routinely used to characterize the
endogenous activator of PPARg. Fatty acids and eicosanoid
derivatives activate PPARg at micromolar concentrations.
PPARg prefers polyunsaturated fatty acids, including the fatty
acids lauric, palmitic, oleic, and essential fatty acids linoleic
acid, linolenic acid, arachidonic acid, 15d-PGJ2 (15-deoxy-
D12,14-prostaglandin J2) and eicosapentaenoic acid. Those
fatty acids activate PPARg directly or act through a derivative
such as nitrolinoleic acid6. Nitroalkene derivatives of linoleic
acid (nitrolinoleic acid, LNO2) are formed via nitric oxide-
dependent oxidative reactions and are found at concentrations
of 500 nmol in the blood of healthy individuals. LNO2 is able
to bind to PPARg directly, and is more robust to activate
PPARg than other endogenous PPARg ligands. LNO2
induces PPARg-dependent macrophage CD-36 expression,
adipocyte differentiation, and glucose uptake at a potency
rivaling TZDs. These observations reveal that NO signal can
be transduced by fatty acid nitration products and PPAR-
dependent gene expression.
15d-PGJ2, a lipid metabolite, was the ﬁrst endogenous ligand
for PPARg discovered in laboratory. Although 15d-PGJ2 is the
most potent natural ligand of PPARg in vitro, its effects remain
to be determined in vivo. Two components of oxidized low
density lipoprotein (ox-LDL), the 9-hydroxy and 13-hydroxy
octadecadienoic acids (HODE), are also potent endogenous
activators of PPARg. Activation of 12/15-lipoxygenase induced
by interleukin (IL)-4 also produced endogenous ligands, 15-
hydroxyeicosatetraenoic acid (15-HETE) and 13-hydroxyocta-
decadienoic acid (13-HETE) for PPARg. However, it remains
unknown if these natural ligands act as physiological PPARg
ligands in vivo.
2.3. NSAIDs and PPARg
Non-steroidal anti-inﬂammatory drugs (NSAID) including
indomethacin, ibuprofen, and fenoprofen have PPARg
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noic, a ﬁsh oil component, and 15d-PGJ2 are two natural
PPARg agonists8. These agents may inhibit inﬂammation
through activation of PPARg as their blood concentration is
sufﬁcient to inhibit production of inﬂammatory cytokines,
such as TNF-a, IL-1 and IL-69. These agents were tested in
fresh human blood monocytes. They suppress expression of
pro-inﬂammatory cytokines in macrophages. They inhibit
PMA or okadaic acid-induced, but not LPS-induced produc-
tion of inﬂammatory cytokines. For inhibition of okadaic
acid-induced cytokine production, potency and IC50 of these
NSAIDs are 15d-PGJ2 (2 mmol/L)4troglitazone (10 mmol/L)4
indomethacin (47 mmol/L)4fenoprofen (133 mmol/L)4ibupro-
fen (142 mmol/L). These IC50 concentrations are in the range of
plasma concentrations under high-dose NSAID therapy, such
as indomethacin (10 mmol/L), ibuprofen (300 mmol/L) and
fenoprofen (250 mmol/L)9. Since PPARg may inhibit inﬂam-
matory cytokine in PPARg dependent and independent man-
ners, the information suggests that PPAR may mediate NSAID
activity to decrease inﬂammatory response. Inhibition of PG
production by suppressing COXII, a NF-kB target gene, will
leads to pain relief. This hypothesis is supported by a recent
study that NF-kB interacts with PPARg through protein–
protein interaction and leads to inhibition of PPARg func-
tion10. These anti-inﬂammatory agents may activate PPARg
indirectly by suppression of co-repressor11.3. Potential TZD substitutes
3.1. HDAC inhibitor
PPARg function is inhibited by nuclear co-repressor in the
absence of ligand (Fig. 2). Upon ligand binding, the co-
repressor complex is replaced by coactivators leading to
activation of PPARg. The corepressor contains catalytic
subunit HDAC3 and regulatory subunit SMRT. In the study
of inﬂammation in insulin resistance, we found that HDAC3
activity is enhanced in the nucleus by TNF-a for PPARg
inhibition11. To block the HDAC3 activity, we used a HDAC
inhibitor, sodium butyrate, in a mouse study to prevent
inﬂammation-induced PPAR inhibition. We found that the
HDAC inhibitor protects the mice from diet-induced insulin
resistance12. The mechanism is related to stimulation of energyFigure 2 Mechanism oexpenditure by the HDAC inhibitor in mice. The same effects
were observed for the classical HDAC inhibitor TSA in our
study. The results suggest that HDAC inhibitor may be a new
class of insulin sensitizer to substitute TZD (Fig. 1). Com-
pared to TZD, HDAC inhibitor is not speciﬁc to a transcrip-
tion factor. It is able to activate many transcription factors
including PPARg, PPARa, CREB and thyroid hormone
receptor by inhibiting HDACs. This broad activity may be
an advantage over a speciﬁc activator of PPARg. For
example, the side effect of rosiglitazone in heart is associated
with its high afﬁnity to PPARg. Pioglitazone has less afﬁnity
to PPARg compared to rosiglitazone. Pioglitazone has fewer
side effects in heart. These results suggest that a drug with low
speciﬁcity to PPARg may be good alternative in the treatment
of type 2 diabetes. An extension of this possibility is that a
drug with multiple targets may be better than those with a
single target. This possibility is supported by the HDAC
inhibitor activity in the improvement of insulin sensitivity in
mice12.3.2. SIRT1 inhibitor
SIRT1, a class III HDAC, was shown to inhibit PPARg
transcriptional activity at the target gene promoter13. Upon
food withdrawal SIRT1 protein binds to the PPARg-respon-
sive genes, including those for fat synthesis, uptake and
storage. SIRT1 represses PPARg by docking with its cofactors
NCoR (nuclear receptor co-repressor) and SMRT (silencing
mediator of retinoid and thyroid hormone receptors). Mobi-
lization of fatty acids from white adipocytes upon fasting is
compromised in SIRT1þ/ mice. Repression of PPARg by
SIRT1 is also evident in 3T3-L1 adipocytes, where over-
expression of SIRT1 attenuates adipogenesis, and RNA
interference of SIRT1 enhances it. In differentiated fat cells,
up-regulation of SIRT1 triggers lipolysis for loss of fat
content. According to this observation, inhibition of SIRT1
will enhanced PPARg function, and improves insulin sensitiv-
ity thereafter. However, this rational is challenged by the
beneﬁcial activities of SIRT1 in others area, such as aging and
liver steatosis14. Inhibition of SIRT1 activity may reduce
lifespan and increase risk of fatty liver. It remains to be tested
if SIRT1 inhibitor is a good candidate for a new class of
insulin sensitizer (Fig. 1).f PPARg activation.
Figure 3 Potential TZD substitutes.
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A reduction in PPARg expression will decrease the transcrip-
tional activity of PPARg. PPARg expression is inhibited by
CREB (cAMP response element binding protein). Herzig et al.
reported that CREB inhibited PPARg expression as CREB
knockdown in vivo leads to 4–5 fold induction of PPARg
mRNA15. Mechanism analysis suggests that CREB inhibits
PPARg through a transcriptional repressor, Hairy Enhancer
of Split (HES-1). CREB induces HES-1 and HES-1 binds to
the gene promoter of PPARg leading to the inhibition.
According to this observation, inhibition of CREB should
increase PPARg expression and PPARg function thereafter.
However, CREB regulates many other genes that are required
for metabolic homeostasis. CREB controls mitochondrial
biogenesis through induction of PGC-1a expression16, and
hepatic gluconeogenesis through PEPCK expression. Inhibi-
tion of CREB may have multiple effects in the body. It is not
known if a CREB inhibitor can improve insulin sensitivity
in vivo (Fig. 1).3.4. Activator of p38 kinase
Regulation of PPARg activity by MAP kinase p38 was ﬁrst
indicated in a study when p38 modulators were used in the
study of adipogenesis17. Later studies conﬁrm that p38
promotes PPARg transcription activity by several groups
using different systems18–20. Regarding the molecular mechan-
ism of p38 activity, it was shown that p38 could phosphorylate
PPARg coactivator (PGC-1) leading to enhancement of the
transcriptional activity of PPARg on the UCP-1 gene promo-
ter18. p38 activity is required for UCP-1 induction by rosigli-
tazone and retinoic acid in fetal brown adipocytes21. In
addition to this possibility, other mechanisms have been
proposed to explain p38 effect on the promotion of PPARg
activity, such as induction of PPARg expression through
NFATc419 and AFT2 interaction with PPARg20. Bone mor-
phogenetic protein 2 (BMP2) promotes the differentiation of
undifferentiated mesenchymal cells into adipocytes. This
activity of BMP2 is blocked by p38 kinase inhibitor. The
mechanism is that the transcriptional activity of PPARg
induced by BMP is blocked by p38 inhibitor20. Activation of
p38 kinase by overexpression of TAK1 and TAB1 did not
affect PPARg expression, but led to the up-regulation of
transcriptional activity of PPARg20. In discussion, Hata
expressed that ‘‘the mechanism for the up-regulation of
PPARg by p38 kinase remains unknown’’. The direct up-
regulation of PPARg by p38 kinase through phosphorylation
is unlikely because PPARg possesses only one consensus
phosphorylation site by MAP kinases at serine112, which is
shown to be phosphorylated by ERK (extracellular signal-
regulated kinase), that inhibits the transcriptional activity of
PPARg22. ATF-2 may mediate p38 activity as ATF-2 is
regulated by p38 kinase. In indomethacin-treated cells, activa-
tion of PPARg is associated with activation of p3823, suggest-
ing that p38 may mediate indomethacin signal for activation
of PPARg. Rosiglitazone (Rosi), as well as retinoic acids 9-cis-
retinoic acid and all-trans-retinoic acid have ‘‘extragenic’’
effects on fetal primary brown adipocytes and induce p38
mitogen-activated protein kinase (p38 MAPK) activation21.
Based on this activity of p38, it is expected that p38 activatorshould enhance PPARg function (Fig. 3). However, p38 activa-
tion may have side effects such as risk of atherosclerosis.
Activation of the p38 MAP kinase pathway is required for foam
cell formation from macrophages exposed to oxidized LDL24.
Foam cell is the major cell typein the atherosclerosis lesion.
3.5. ERK inhibitor
Persistent activation of ERK was shown to inhibit PPARg
activity through a direct phosphorylation22 (Fig. 1). Persistent
increase in ERK activity leads to the inhibition of PPARg
function in the tyrosine kinases-1 (Dok1) KO mice25. How-
ever, it was shown that transient activation of MEK/ERK
signaling promotes PPARg activity during the differentiation
of 3T3-L1 preadipocytes26. It is not clear if an ERK inhibitor
will be able to enhance PPARg function in vivo. If it does, it
may be worth to test its activity in the regulation of insulin
resistivity.
3.6. NO inducer
NO may enhance PPARg function through generation of
nitrolipid (Fig. 1). Nitrolinoleic acid (LNO2) is a product of
linoleic acid after reaction with NO (Nitric Oxide). Nitrolino-
leic acid was reported to be a ligand of PPARg6. Additionally,
NO may activate PPARg through activation of cGMP. NO
was reported to increase energy expenditure through a signal-
ing pathway of cGMP-PPARg-PGC-1-UCP127. In the study,
eNOS/ mouse was used and NO effect was observed in cells
including 3T3-L1 adipocytes. It was shown that NO can
activate the cGMP signaling pathway in 3T3-L1 adipocyte,
monocytes and other types of cells27. PPARg activity is
enhanced by NO donors S-nitrosoacetylpenicillamine (SNAP,
100 mmol/L), S-nitroso-L-glutathione (GSNO) and cGMP
analog 8Br-cGMP (1 mmol/L). The activity is reduced by
NO scavenger oxyhemoglobin (50 mmol/L), nitric oxide
synthase (NOS) inhibitor L-NAME, and selective guanylate-
cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ, 1 mmol/L). These data suggest that NO inducer may
activate PPARg.
3.7. Cdk5 inhibitor
It has been reported recently that Cdk5 (cyclin-dependent
kinase 5) inhibits PPARg function in insulin sensitization
(Fig. 1)28. Cdk5 is extensively studied in the neuronal cells.
Cdk5 is involved in the regulation of various physiological
processes of neuronal cells from survival, migration and
differentiation, to synaptogenesis, synaptic plasticity and neu-
rotransmission. Dysregulation of Cdk5 has been demonstrated
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generative disorders, such as Alzheimer’s disease. A new study
reports that Cdk5 is activated in adipocytes in mice by high-fat
diet28. In this study, Cdk5 is shown to phosphorylate the
nuclear receptor PPARg at serine 273 leading to dysregulation
of a large number of genes in obesity including adiponectin.
The phosphorylation of PPARg by Cdk5 is blocked by
rosiglitazone. This inhibition works both in vivo and in vitro,
and is completely independent of gene transcription from
PPARg activation. The inhibition is tightly associated with
the anti-diabetic effects of rosiglitazone. These ﬁndings suggest
that Cdk5-mediated phosphorylation of PPARg may be
involved in the pathogenesis of insulin resistance, and present
an opportunity for development of new class of anti-diabetic
drugs from Cdk inhibitors. These possibilities remain to be
tested in vivo.
3.8. PPARg is required for adipose tissue growth
PPARg is most abundant in fat tissues, and dysfunction of
PPARg contributes to insulin resistance. The nuclear receptor
PPARg is a member of peroxisome proliferator-activated
receptor (PPAR) family that includes PPARa, PPARg, and
PPARd (PPARb). There are two isoforms in PPARg,
PPARg1 and PPARg2. PPARg1 is expressed ubiquitously
and PPARg2 is mainly expressed in adipocytes. The biological
activities of PPARg are very broad, but it is generally accepted
for a master transcriptional regulator of lipid and glucose
metabolism. Activation of PPARg promotes adipocyte differ-
entiation and triglyceride accumulation in adipocytes. Gene
knockout studies consistently suggest that PPARg is required
for adipose tissue development and the tissue growth in
response to positive energy balance. Four groups indepen-
dently made fat-speciﬁc knockout (KO) mice and published
the metabolic phenotypes of the mice all in PNAS29–32. The
studies suggest that PPARg KO in fat prevents obesity and
insulin resistance in the mice fed a high-fat diet. In the last
report, the mice have an increase in food intake, spontaneous
physical activity and energy expenditure32. The increased
energy expenditure may provide protection against obesity
and insulin resistance in the mice. The energy expenditure is
likely a result of increased supply of fatty acids to mitochon-
dria since the adipose tissues do not have sufﬁcient room to
store the fatty acids. The study suggests that restriction of
PPARg function before obesity may promote energy expen-
diture and prevent development of dietary obesity leading to
preservation of insulin sensitivity. However, activation of
PPARg induces generation of new adipocyte through pre-
adipocyte differentiation to increase storage capacity of
adipose tissue. This action in adipose tissue allows PPARg
agonist to improve insulin sensitivity by reducing blood lipids
and preventing ectopic fat deposition, which induces lipotoxi-
city in liver and skeletal muscle in the pathogenesis of insulin
resistance. Activation of PPARg in adipose tissue is the
molecular mechanism by which PPARg ligand improve insulin
sensitivity in patients.4. Summary
Current literature suggests that TZD-based drugs are facing
more and more challenges from the severe side effects in thecardiovascular system and bladder cancer. There have been
four TZD-based drugs and all of them have life-threatening
side effects. Although the side effects are different among the
four drugs, the history of TZD-based drugs suggests that this
class of insulin sensitizer will reach their end sooner or later.
With prevalence of type 2 diabetes and limited number of
insulin sensitizers, there is a huge demand for a new class of
drug that is better than TZDs in safety. In this review, several
approaches are discussed in search for the new class of drugs.
These include HDAC inhibitor, SIRT1 inhibitor, Cdk5 inhi-
bitor, ERK inhibitor, CREB inhibitor and p38 activator
(Fig. 3). It appears that a HDAC inhibitor holds a strong
promise. It improves insulin sensitivity, stimulates energy
expenditure and suppresses cancer. This example suggests that
a drug for multiple targets may be better than those for a
single target in the treatment of insulin resistance and type 2
diabetes.Acknowledgment
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